Route 92 Medical Collects $50 Million in Financing

Route 92 Medical Inc. has completed a $50 million growth financing, led by Novo Holdings, with additional support coming from new investor Sectoral Asset Management, and returning patrons U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group. 

The financing’s proceeds will help fund the next phase of Route 92 Medical’s growth strategy by helping to accelerate global commercial expansion, advance clinical evidence to support the broader adoption of the company’s neurovascular procedural approach and invest in continued product innovation across its platform.

“We’ve seen rapid growth in the adoption of our products over the past year, attributable to the clinical performance of our Monopoint approach, and the growth and dedication of our commercial organization,” Route 92 Medical Founder/CEO Tony Chou, M.D., said. “We’re on a mission to improve outcomes for patients suffering from acute ischemic stroke, and our sales are a testament to the differentiated, physician-preferred attributes of our neurovascular thrombectomy solutions.”

The company’s neurovascular portfolio includes the HiPoint Reperfusion System, featuring the Monopoint approach—the first “super-bore” aspiration catheter with a mono-axial procedural approach and a 0.088-inch inner diameter that is cleared by the U.S. Food and Drug Administration (FDA) to treat large vessel occlusions, the cause of many acute ischemic strokes. It joins a suite of purpose-built stroke treatment solutions including the HiPoint 70 Reperfusion System, FreeClimb 70 Reperfusion System, FreeClimb 54 Reperfusion System, and the FreeClimb 88 Access System. 

This financing news follows the completion of Route 92 Medical’s SUMMIT MAX clinical trial, a 250-patient, multicenter, prospective, randomized, and controlled endovascular stroke thrombectomy study that evaluated the safety and efficacy of the HiPoint Reperfusion System featuring the Monopoint approach. Data from the trial demonstrated favorable safety performance and the highest first-pass effect ever reported in a randomized, controlled endovascular stroke thrombectomy study. The investigational device exemption (IDE) trial results were submitted to the FDA and, in May 2025, the HiPoint Reperfusion System received neurothrombectomy marketing clearance from the FDA.

Accordingly, Route 92 Medical claims it is the first neurovascular intervention company to receive clearance for direct aspiration of a stroke-causing thrombus with a super-bore 0.088-inch catheter in the neurovasculature. The company’s products work harmoniously as complete systems to improve the efficiency of endovascular thrombectomy procedures, enabling clinicians to quickly restore blood flow to a patient’s brain following acute ischemic stroke, the most common type of stroke affecting patients today. 

“We believe Route 92 Medical is positioned for long-term growth with robust manufacturing capacity, a clearly defined market, and a well-differentiated product portfolio,” Sectoral Asset Management Co-Founder/Partner Michael Sjöström stated. “Our investment aims to accelerate its commercial growth, helping the company reach many more hospitals and patients.”

Route 92 Medical aims to improve outcomes for patients undergoing neurovascular intervention through cutting-edge engineering and innovative product design. Founded by physicians, the company collaborates with neurovascular clinicians to solve the biggest challenges in neurointervention and deliver meaningful, differentiated solutions that promote clinical success.